AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
2min chapter
Swiss lawmakers criticise ‘years of mismanagement’ at Credit Suisse
World Business Report
Novo Nordisk Faces Setback with New Weight Loss Drug
This chapter examines the sharp decline in Novo Nordisk's share prices following the underwhelming results of their new weight loss drug, Cagrysema. With a performance below market expectations, the discussion emphasizes the implications for the company's future in the burgeoning $130 billion weight loss drug market.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode